Company intelligence / Profile preview

Beijing Kanova Biopharmaceutical

Ownership: Private
Development stage: Phase 1

Overview

The first Phase III clinical trial successfully met its primary endpoint in 2024 with their lead antibody drug candidate. The pipeline includes advanced-stage candidates progressing through clinical development with promising results in autoimmune indications like ankylosing spondylitis and asthma.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies and innovative combination therapies
Industry: Biotech

Drug pipeline

1 asset

XKH001

Phase 1

Indications: Asthma

Partnerships

No specific major pharma partnerships disclosed publicly; however involved in licensing out assets such as XKH004 previously. Collaborations welcomed domestically and internationally per company statements.

Beyond the preview

Go deeper on Beijing Kanova Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kanova Biopharmaceutical.

Explore the full profile